We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




A Single Gene May Regulate Differentiation of Embryonic Cells

By LabMedica International staff writers
Posted on 31 Dec 2008
Israeli cell biologists have identified the gene whose enzyme product is the main regulator of the gene activity that separates pluripotent embryonic cells from differentiated adult cell types.

Early in the fetal developmental process embryonic cells, which have the potential to develop into all the tissues that make up the organs in the body, come under tight and directed genetic control. More...
When this mechanism kicks in, cells are locked into a specific phenotype. This means, for example, that liver cells can make new liver cells but not lung cells.

In modern medicine there is great interest in the used of pluripotent cells to treat disease syndromes characterized by the loss or death of cells. The use of embryonic tissue to treat Parkinson's disease is one example. However, use of embryonic tissue from fetal sources is complicated by ethical considerations. Another possibility is to return adult cells to an embryonic state. These cells would then be channeled into developing into a different type of tissue.

To date, attempts to convince adult cell types to regress have met with only limited success. Thus, data published in the November 2008 issue of the journal Nature Structural and Molecular Biology by researchers from the Hebrew University of Jerusalem (Israel) is of particular relevance. This study reported that a single gene known as G9a controls the differentiation process. G9a encodes for a histone methyltransferase that affects gene activity in two ways. By catalyzing the methylation of histone proteins, it blocks gene reactivation, and by controlling the methylation of DNA, it prevents reprogramming of genes to the undifferentiated state. Thus, G9a keeps cells locked into their differentiated phenotypes.

Armed with the knowledge generated in this study it may become possible to control or reverse G9a activity in order to produce embryonic-like cells from adult tissues.

Related Links:
Hebrew University of Jerusalem



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.